Pathways - manually collected, often from reviews:
OpenBEL Selventa BEL large corpus:
Complex of EGFR-IRS1
→
EGFR
(increases, EGFR/IRS1 Activity)
Knowlden et al., Breast Cancer Res Treat 2008* Evidence: Significantly, challenge of Tam-R cells with the EGFR-selective tyrosine kinase inhibitor gefitinib, for 7 days, reduces IRS-1/EGFR association